Glaukos Says iStent inject Data Superior to iStent

■ Glaukos Corporation said an independent, international case series published in Ophthalmology and Therapy showed that iStent inject Trabecular Micro-Bypass System achieved a greater absolute IOP reduction and a higher medication-free rate at 1 year postoperatively when compared to the first-generation iStent Trabecular Micro-Bypass Stent. All subjects in the case series received stents in combination with cataract surgery.

This real-world retrospective case series included 137 eyes with cataract and mild-to-moderate glaucoma or ocular hypertension. More than 73% of eyes in both groups were in early states of glaucoma disease progression, and approximately 22% had prior glaucoma surgery. All procedures were performed by David Manning, MD, at a single practice in Australia. Consecutive patients received either iStent inject (n=70) or iStent (n=67), based on availability in the Australian market.

At 1 year postoperatively, mean IOP in eyes receiving iStent inject decreased 1.8 mmHg more than iStent eyes, based on the decrease in absolute IOP for each group. In addition, 92.9% of iStent inject eyes were medication-free at 1 year postoperatively, and 76.1% of the iStent eyes were medication-free at 1 year postoperatively. The safety profile was favorable in both groups, with few adverse events and no secondary glaucoma surgeries.